Alex Tong-Long Lin, Mou-Jong Sun, Hui-Lung Tai, Chuang Chi Yao, Shih-Tsung Huang, Nick Wang, Y. D. Zhao, Julie Beyrer, Meghan Wulster-Radcliffe, Louise Levine, Curtis Chang, Lars Viktrup
2008.1.25BMC Urology
tlooto Summary
A two-factorial structure of the PRAFAB questionnaire was suggested, measuring the stress UI leakage severity items and the perceived symptom impact items, suggesting a two-factorial structure of the PRAFAB questionnaire.
Abstract
Background This manuscript compares the efficacy and safety of duloxetine with placebo in Taiwanese women with SUI. Methods Taiwanese women with SUI were were randomly assigned to placebo (n = 61) or duloxetine 80 mg/day (n = 60) in this double-blind, 8-week, placebo-controlled study. Outcome variables included: incontinence episode frequency (IEF), Incontinence Quality of Life questionnaire (I-QOL) scores, and Patient Global Impression of Improvement rating (PGI-I). Results Decrease in IEF was significantly greater in duloxetine-treated than placebo-treated women (69.98% vs 42.56%, P < .001). No treatment differences in I-QOL scores were significant. There were significant differences in PGI-I rating. Treatment-emergent adverse events (TEAEs) were experienced by more duloxetine-treated than placebo-treated women (80.0% vs 44.3%; P < .001). Discontinuations due to adverse events were significantly greater for duloxetine-treated than placebo-treated women (26.7% vs 6.6%; P = .003). Conclusion Data provide evidence for the safety and efficacy of duloxetine for the treatment for Taiwanese women with SUI. Trial Registration ClinicalTrials.gov Identifier: NCT00475358
Citation format
LIN, Alex Tong-Long, et al. BMC urology biomed central. BMC Urology, 2008, 8: 2–2.